Price and clinical benefit of cancer drugs in Canada, 2011-2020

Jenei, Kristina, Meyers, Daniel and Gyawali, Bishal (2023) Price and clinical benefit of cancer drugs in Canada, 2011-2020. JAMA network open. ISSN 2574-3805

Text (Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020) - Published Version Available under License Creative Commons Attribution. Download (423kB)

Abstract

Cancer drug prices have increased exponentially in the past decade and several studies demonstrate an increasing disconnect between clinical benefit and prices for cancer drugs approved by the FDA or the EMA.1,2 This disconnect seemed to exist even in the setting of central price negotiations in Italy.3 However, this has not been studied for Canada. This study examines the association between approval characteristics, clinical benefit, and prices for cancer drugs recommended for reimbursement in Canada by the Canadian Agency for Drug and Technology in Health (CADTH).

Item Type:	Article
Additional Information:	© 2022 The Author(s).
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	16 Dec 2022 11:36
Last Modified:	17 Oct 2024 17:58
URI:	http://eprints.lse.ac.uk/id/eprint/117628

Actions (login required)

View Item